Evidence map›Paper›PMID 38013438›Full record

ReviewCurrent drug delivery2025

Targeted Polymeric Nanoparticles as a Strategy for the Treatment of Glioblastoma: A Review.

Geanne Aparecida de Paula, Mariana Carlomagno de Paula, Jessyca Aparecida Paes Dutra, Suzana Gonçalves Carvalho, Leonardo Delello Di Filippo, Janaína Cecília Oliveira Villanova, Marlus Chorilli

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Geanne Aparecida de PaulaSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil.ORCID 0000-0002-8637-6783
Mariana Carlomagno de PaulaSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil.
Jessyca Aparecida Paes DutraSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil.
Suzana Gonçalves CarvalhoSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil.
Leonardo Delello Di FilippoSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil.
Janaína Cecília Oliveira VillanovaCenter for Exact, Natural and Health Sciences - CCENS, Federal University of Espírito Santo (UFES), Alegre, Espírito Santo, Brazil.
Marlus ChorilliSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil.
Universidade Estadual Paulista (Unesp) · BRUniversidade Federal do Espírito Santo · BR

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) 001
6 · The paper itself

Abstract

Glioblastoma multiforme is the most common and aggressive malignant tumor that affects the central nervous system, with high mortality and low survival. Glioblastoma multiforme treatment includes resection tumor surgery, followed by radiotherapy and chemotherapy adjuvants. However, the drugs used in chemotherapy present some limitations, such as the difficulty of crossing the bloodbrain barrier and resisting the cellular mechanisms of drug efflux. The use of polymeric nanoparticles has proven to be an effective alternative to circumvent such limitations, as it allows the exploration of a range of polymeric structures that can be modified in order to control the biodistribution and cytotoxic effect of the drug delivery systems. Nanoparticles are nanometric in size and allow the incorporation of targeting ligands on their surface, favoring the transposition of the blood-brain barrier and the delivery of the drug to specific sites, increasing the selectivity and safety of chemotherapy. The present review has described the characteristics of chitosan, poly(vinyl alcohol), poly(lactic-coglycolic acid), poly(ethylene glycol), poly(β-amino ester), and poly(ε-caprolactone), which are some of the most commonly used polymers in the manufacture of nanoparticles for the treatment of glioblastoma multiforme. In addition, some of the main targeting ligands used in these nanosystems are presented, such as transferrin, chlorotoxin, albumin, epidermal growth factor, and epidermal growth factor receptor blockers, explored for the active targeting of antiglioblastoma agents.

Indexed as

Antineoplastic AgentsBrain NeoplasmsDrug Delivery SystemsGlioblastomaNanoparticlesPolymersAnimalsBlood-Brain BarrierHumansAntineoplastic AgentsPolymersactive targetingBrain cancerdrug delivery systemsfunctionalized nanoparticles.polymeric nanocarriersselectivity

Identifiers

PMID38013438
OpenAlexW4389097635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.